As­traZeneca takes a chance on the STING path­way with F-star

Af­ter a slew of Big Phar­ma com­pa­nies and biotechs walked away from the STING path­way in the last few years, As­traZeneca is ap­proach­ing the field with a new bet on the drug class’ next gen­er­a­tion.

The British drug­mak­er is team­ing up with F-star Ther­a­peu­tics on a slate of pre­clin­i­cal STING in­hibitor com­pounds, the com­pa­nies an­nounced Thurs­day morn­ing. It’s a mod­est sum as these things go, with $12 mil­lion up­front and over $300 mil­lion in mile­stones, plus sin­gle-dig­it roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER